Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Meta-analysis on the effects of octreotide on tumor mass in acromegaly.

Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S.

PLoS One. 2012;7(5):e36411. doi: 10.1371/journal.pone.0036411. Epub 2012 May 4.

2.

Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.

Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.

Horm Res. 2004;62(5):227-32. Epub 2004 Oct 11.

PMID:
15477693
3.

Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.

Jallad RS, Musolino NR, Salgado LR, Bronstein MD.

Clin Endocrinol (Oxf). 2005 Aug;63(2):168-75.

PMID:
16060910
4.

Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.

Carlsen SM, Svartberg J, Schreiner T, Aanderud S, Johannesen O, Skeie S, Lund-Johansen M, Fougner SL, Bollerslev J; POTA study group.

Clin Endocrinol (Oxf). 2011 Jun;74(6):736-43. doi: 10.1111/j.1365-2265.2011.03982.x.

PMID:
21521254
5.

The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response.

Luque-Ramírez M, Portoles GR, Varela C, Albero R, Halperin I, Moreiro J, Soto A, Casamitjana R; Spanish Multicentre Group for the Study of Acromegaly.

Horm Metab Res. 2010 Jan;42(1):38-44. doi: 10.1055/s-0029-1239506. Epub 2009 Oct 1.

PMID:
19798622
6.

Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.

Plöckinger U, Quabbe HJ.

Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. Epub 2005 Apr 4.

PMID:
15806331
7.

Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.

McKeage K, Cheer S, Wagstaff AJ.

Drugs. 2003;63(22):2473-99. Review.

PMID:
14609359
8.

Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?

Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.

Clin Endocrinol (Oxf). 2007 Aug;67(2):310-5. Epub 2007 Jun 6.

PMID:
17555503
9.

First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.

Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.

Clin Endocrinol (Oxf). 2006 Mar;64(3):342-51.

PMID:
16487447
10.

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D.

J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73. Epub 2005 May 10.

PMID:
15886238
11.

Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.

Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T.

Endocr J. 2006 Feb;53(1):125-32.

12.

Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.

Shen M, Shou X, Wang Y, Zhang Z, Wu J, Mao Y, Li S, Zhao Y.

Endocr J. 2010;57(12):1035-44. Epub 2010 Nov 16.

13.

Improvement of acromegaly after octreotide LAR treatment.

Mangupli R, Lisette A, Ivett C, Paul C, de los Ríos Victoria C, Luis CJ.

Pituitary. 2003;6(1):29-34.

PMID:
14674721
14.

Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study.

Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A, Ragazzoni F, Pigliaru F, Alberti D, Ferrara R, Angeletti G.

J Endocrinol Invest. 2005 Dec;28(11):978-83.

PMID:
16483175
15.

Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.

Lundin P, Edén Engström B, Karlsson FA, Burman P.

AJNR Am J Neuroradiol. 1997 Apr;18(4):765-72.

16.

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A.

J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10. Epub 2005 Apr 12.

PMID:
15827109
17.

Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.

Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC.

Clin Endocrinol (Oxf). 2009 May;70(5):757-68. doi: 10.1111/j.1365-2265.2008.03441.x. Epub 2008 Oct 6.

PMID:
19178516
18.

[Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].

Laczi F, Magony S, Julesz J.

Orv Hetil. 2002 May 12;143(19 Suppl):1062-6. Hungarian.

PMID:
12063861
19.

Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months.

Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Grasso LF, Lombardi G.

J Clin Endocrinol Metab. 2008 Sep;93(9):3436-42. doi: 10.1210/jc.2008-0424. Epub 2008 Jul 1. Erratum in: J Clin Endocrinol Metab. 2008 Oct;93(10):4162.

PMID:
18593770
20.

Octreotide treatment of acromegaly. A randomized, multicenter study.

Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, et al.

Ann Intern Med. 1992 Nov 1;117(9):711-8.

PMID:
1416572

Supplemental Content

Support Center